Tampilkan postingan dengan label Bipartisan. Tampilkan semua postingan
Tampilkan postingan dengan label Bipartisan. Tampilkan semua postingan

Senin, 07 Agustus 2017

Bringing down pharmaceutical costs

Bringing down pharmaceutical costs


Today's Managing Health Care Costs Number is  250%

One area of bipartisan agreement is the desire to lower pharmaceutical prices.   As always, there are good ideas with downsides, bad ideas with upsides, and many ideas that are likely to  have unanticipated consequences.   Annual prescription drug costs are expected to increase to $597 billion by 2025- a 250% increase from 2007, so there is a real imperative to address pharmaceutical costs. 

Among the ideas that are being discussed:

  1. Ease regulatory burden to allow faster generics to market. 
    The real problem here has generally been litigation from incumbent brand name products and lack of competition for non-blockbuster generics, most of which have only 1 or 2 manufacturers - leaving them vulnerable to steep price increases.  Let's make it harder to take legal steps to block new generics, easier to get approval for biosimilars, and allow importation of generics from other countries with good regulatory schemes when there is a shortage.
     
  2. Allow 'value based pricing.'
    No one is preventing value based pricing now- but we should think hard about whether this is really what we want.   Airlines use value based pricing (so that business travelers not staying over a Saturday night pay higher prices).   Some pharmaceutical companies want to be able to charge different prices based on the indication for a drug - but this is likely to lead to higher overall costs (and huge administrative headaches).  Her's a pretty positive assessment of  indication specific pricing from ICER (2015), and here's a perspective from New England Journal of Medicine (2017) pointing to likely higher overall costs. Reports from countries that implemented warrantees are disappointing; these were hard to reconcile and probably led to higher prices. A report from Propublica  begins:

More than a decade ago, Italy tried a novel approach to help bring down drug costs: asking pharmaceutical companies to return money to the national health system if some of their medicines failed to work as expected. The effort largely flopped

  1. "March in" and demand that patent-holders offer drugs for less, or seize the patent
    Some countries like Brazil and India have effectively done this- but they are much smaller markets than the US and they tend to be home to generic and not brand manufacturers.   This might be a more effective threat than actual policy.  Some Democrats have suggested that the NIH should exercise its 'march in' rights. Many think this would lead to decreased investment in pharma and less innovation - and such a move seems unlikely in an Administration seeking to diminish the role of government.
     
  2. Allow Medicare to negotiate drug prices
    Right now Medicare Part D is administered through thousands (!) of different plans each of which negotiates with the pharmaceutical industry.  That kind of fragmentation leads to higher prices for Medicare, the largest purchaser of drugs in the country.   Medicare pays more than the Veterans Administration or Medicaid for drugs.  It's hard to imagine disassembling the current Medicare Part D system in the next few years - although it would be easy to imagine some central negotiation for high cost medications that could be excluded from the Medicare Part D plans.
     
  3. Stop drug company direct to consumer advertising
    This would make TV viewing much more pleasurable - but the Supreme Court has decided that commercial speech is protected by the First Amendment, so this would require a constitutional amendment.
     
  4. Direct the FDA to consider cost effectiveness when it approves new medications
    This would require a new statute and new enabling regulations. Countries like the UK which have this in place have found that it does lower access to some new innovative drugs, and this is unpopular.  Perhaps this isn't unpopular at the level of fictional "death panels," but it would be hard to see such legislation gaining broad traction in the next few years.
     
  1. Mandate generic substitution
    Fourteen states mandate that a generic be dispensed where available unless the physician explicitly orders a brand name, and this dramatically increases generic substitution rate.  49 states allow pharmacist generic substitution based on pharmacist discretion - and only Oklahoma prohibits even this.  This battle must be fought state by state, and a small amount of lobbying goes a long way in most state legislatures.
     
  1. Provider risk sharing
    Physicians write prescriptions - and they would pay much more attention to the cost of drugs if their organizations bore financial responsibility for drug costs.  Providers do take risk for drug spending in some accountable care or bundled payment arrangements.  Provider risk sharing could also lead to physicians failing to prescribe valuable but expensive drugs, or "dumping" of patients with known chronic diseases that have expensive drug treatment. 

I'm not confident we'll lower pharmaceutical prices a lot over the next few years- especially given the new genomic drugs in the offing.  And I'm worried that the cost savings from generics might diminish through consolidation in that industry. But I'm heartened by the discussion and the bipartisan concern. Elements of the approach to lowering drug cost inflation that are being discussed now could serve as the foundation to lower costs in the years to come.
  

Selasa, 01 Agustus 2017

 Maybe a bipartisan health plan is possible?

Maybe a bipartisan health plan is possible?


Today's Managing Health Care Costs Number is 5
 

John McCain rose to the occasion last week and cast one of 51 deciding votes against the ill-named Health Care Freedom Act, aka skinny repeal, which would have led to loss of health coverage for 16 million Americans.    The "repeal and replace Obamacare" movement has been declared dead, although yesterday President Trump tweeted continued threats to blow up the exchanges by not continuing Cost Sharing Reduction payments, and even threatened to stop paying the employer portion of health care premiums for Congressmen and their staffers.  So the effort to repeal is not dead.

A bipartisan group of 40 moderate Republicans and Democrats in the House has just offered ` to increase stability of the individual markets and lower health care costs.  This was first reported on Politico on Sunday.  I'm not confident that Paul Ryan would ever bring this bill up for debate - and if he did, it's not clear there are enough votes to pass it.  But there are some good ideas here.  The five pillars of this legislation

  1. Fund the Cost Sharing Reductions.  They are necessary for exchange policies to be useful for those with low incomes (but over 133% of the federal poverty level), to be sure that their out of pocket costs for care don't make their ACA plans useless.  The dollars in the federal budget are small, and it's likely that health plans would raise premiums (which the feds are also on the hook to pay) -so the winners here will be those with over 400% of FPL income who get insurance on the exchange without subsidies.  This will be hard for Republicans to swallow - it increases federal expenditures.
     
  2. Create a dedicated stability fund for the states.  This could be used to create reinsurance so that health plans didn't have to worry so much about enrolling the sickest of the sick - which would be an important complement for "guarantee issue."  Like funding CSRs, this would be a big Republican give.
     
  3. Exempt employers with 51-499 employees from the employer mandate.   No employer has paid employer mandate penalties so far as this mandate has been delayed, and most employers would intend to continue employer coverage regardless.  This could lead to some losing insurance, though - so it will be a bitter pill for Democrats committed to universal coverage.
     
  4. Repeal of medical device tax.  This tax has also been delayed - it would have raised $20 billion over 10 years.   It's not critical to the success of the Affordable Care Act or the individual exchanges.  Congressmen and women on both sides of the aisle would be fine with this.
     
  5. Promote sale of health plans across state lines.   This is already live in a number of states, and the health plans have expressed no interest.   States with more rigorous regulation of their health care insurance markets will continue to oppose federal preemption of their regulation, and further fragmentation of the health plan markets could lead to higher prices.   States will also worry rightly that a state far away won't be as vigorous in insuring health plan financial stability.  Democrats won't like this - especially since the regulations will be written by the Trump Administration. But getting CSRs and a reinsurance type fund might be worth the dangers this could cause.  Here's an older KFF brief on the subject, and a recent Sarah Kliff review (see item (4))

So - perhaps my estimation of the potential for a bipartisan approach was needlessly pessimistic.   The Republicans might not share the Democratic commitment to universal coverage, but they are not willing to wrench coverage away from millions.  The Democrats know they are in the minority - and appear willing to accept some painful compromises.

Again - it's not clear that the House will act on this proposal - but it's heartening to see some bipartisan efforts to improve health care take root.

Senin, 06 Maret 2017

 Doubts on payment reform could stall health care transformation

Doubts on payment reform could stall health care transformation


Payment reform on its own will not cure our high medical costs.  We need to make fundamental changes in the way we deliver care - and that won't happen just because some care is no longer paid for via "fee for service."  

Changes that we need include:
  • Advancing "disruptive innovations," that lower costs dramatically even if they lack some elements of traditional care. (This includes midwifery delivery in birth centers for low risk pregnancy, and lightweight ultrasounds that can be used at the point of care)
  • Increased coordination among providers
  • Better "hot spotting" to identify the highest risk patients and prevent hospital admissions
  • Evidence based use of imaging
  • Providers who are sensitive to resource cost of what they order

Right now, health care providers are doing well overall - and changing the underlying business is a threat to that success.   Payment reform provides the necessary threat to push integrated delivery networks and other provider organizations to seriously consider making changes that could lower revenue. 

So while payment reform alone won't lead to higher value care, lack of the viable threat of payment reform could halt progress on health care delivery redesign.   Why should a CFO agree to an expensive program to halt high margin but preventable hospital admissions?

I co-teach a provider payment course in a graduate degree program for mid-career physician executives at the Harvard TH Chan School of Public Health. Watching these talented physicians and learning about the efforts they are making to transform health care in their organizations has made me guardedly optimistic about the chances that the "accountable care" movement could substantially improve health care value.

This weekend, the buzz was around a comment by one of the professors that "MACRA is dead."   MACRA, the Medicare Access and CHIP Reauthorization Act, which eliminated the physician "sustainable growth rate (SGR)" regulations which would have cut Medicare professional reimbursement by more than a quarter, defined specific Medicare penalties for providers who were not effectively using electronic medical records, and allowed physicians participating in alternative payment models to avoid these penalties.

MACRA was passed by a bipartisan majority in 2015 (54-45 in the Senate and 392-37 in the House).  So some have felt that the payment reform in MACRA is "safe."   I'm afraid I disagree.

MACRA had the support of many conservative Republicans who voted for this in part because it eliminated the hated SGR. Many, including now-HHS Secretary Tom Price, have argued that the Obama Administration rulemaking around the bill would create undue demands on physicians.  Price argued that payment reform should be voluntary.    But voluntary bundled payments don't create the burning platform necessary to drive change in health care delivery.

Some delivery systems that have been deeply committed to transforming themselves will push ahead with efforts to improve quality of care and lower costs.  But many systems are likely to put such efforts on the slow track, as they wait to see whether the Trump administration will do the hard work of administrative rulemaking to support payment reform.

As we discussed the prospects for payment reform, I sensed a deep sigh of disappointment among these physician executives who have devoted their professional lives to redesigning health care.